Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05754645
Other study ID # NL80155.078.22/OZBS72.21318
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 21, 2022
Est. completion date July 21, 2026

Study information

Verified date February 2023
Source Erasmus Medical Center
Contact Nicole Schenkelaars, MD
Phone +31627530793
Email n.schenkelaars@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research aims to elucidate an underlying mechanism of maternal obesity induced pregnancy and longterm health complications for mothers and their offspring.


Description:

With the increasing global prevalence of obesity, pregnancy problems related to maternal obesity are increasingly occurring. Microbial gut symbiosis plays an important role in health, with dysbiosis being associated with diseases such as obesity. Of interest are pregnancy, dietary patterns and pre- or probiotics that affect the composition of the gut microbiome. The microbiome itself can influence many physiological processes, such as immune responses (production of microbial products) and the nutrient-dependent one-carbon metabolism. It is hypothesized that gut dysbiosis, due to maternal obesity, during pregnancy can be considered an endogenous chronic stressor causing impaired immune response and carbon metabolism. Both processes result in excessive oxidative stress, detrimental to cell replication, differentiation and epigenetic programming of maternal and infant tissues. Together, these biological disturbances contribute to placental and vascular dysfunction, leading to an increased risk of preeclampsia or gestational diabetes mellitus. Vertical (during pregnancy) and horizontal (during delivery) transmission of gut dysbiosis from mother to newborn and epigenetic placental and foetal changes may ultimately lead to macrosomia and obesity in children. Therefore, the differences between the gut and vaginal microbiome, maternal and fetal immune responses and one-carbon metabolism in obese versus normal-weight pregnant women will be analysed.


Recruitment information / eligibility

Status Recruiting
Enrollment 110
Est. completion date July 21, 2026
Est. primary completion date July 21, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Participation in Predict study - Preconceptional women who wish to become pregnant or pregnancy <13 weeks of gestational age. - BMI > 30 kg/m2 or 18-25 kg/m2 - Understanding of Dutch in speaking and reading - Willingness to give written informed consent Exclusion Criteria: - Age < 18 years and > 45 years. - =13 weeks of gestational age - Multiple pregnancy - Smoking - Gastro-intestinal diseases, heart diseases, liver, pancreas and kidney diseases. - Use of antibiotics < 2 weeks before sampling - Pre-existent diabetes mellitus

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood withdrawal
venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself

Locations

Country Name City State
Netherlands Erasmus MC Rotterdam Zuid-Holland

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

References & Publications (10)

Elderman M, Hugenholtz F, Belzer C, Boekschoten M, de Haan B, de Vos P, Faas M. Changes in intestinal gene expression and microbiota composition during late pregnancy are mouse strain dependent. Sci Rep. 2018 Jul 3;8(1):10001. doi: 10.1038/s41598-018-28292-2. — View Citation

Gaillard R, Durmus B, Hofman A, Mackenbach JP, Steegers EA, Jaddoe VW. Risk factors and outcomes of maternal obesity and excessive weight gain during pregnancy. Obesity (Silver Spring). 2013 May;21(5):1046-55. doi: 10.1002/oby.20088. — View Citation

Kuhle S, Muir A, Woolcott CG, Brown MM, McDonald SD, Abdolell M, Dodds L. Maternal pre-pregnancy obesity and health care utilization and costs in the offspring. Int J Obes (Lond). 2019 Apr;43(4):735-743. doi: 10.1038/s41366-018-0149-3. Epub 2018 Jul 13. — View Citation

Mission JF, Marshall NE, Caughey AB. Pregnancy risks associated with obesity. Obstet Gynecol Clin North Am. 2015 Jun;42(2):335-53. doi: 10.1016/j.ogc.2015.01.008. — View Citation

Morgan KL, Rahman MA, Macey S, Atkinson MD, Hill RA, Khanom A, Paranjothy S, Husain MJ, Brophy ST. Obesity in pregnancy: a retrospective prevalence-based study on health service utilisation and costs on the NHS. BMJ Open. 2014 Feb 27;4(2):e003983. doi: 10.1136/bmjopen-2013-003983. — View Citation

Rousian M, Schoenmakers S, Eggink AJ, Gootjes DV, Koning AHJ, Koster MPH, Mulders AGMGJ, Baart EB, Reiss IKM, Laven JSE, Steegers EAP, Steegers-Theunissen RPM. Cohort Profile Update: the Rotterdam Periconceptional Cohort and embryonic and fetal measurements using 3D ultrasound and virtual reality techniques. Int J Epidemiol. 2021 Nov 10;50(5):1426-1427l. doi: 10.1093/ije/dyab030. No abstract available. — View Citation

Schoenmakers S, Steegers-Theunissen R, Faas M. The matter of the reproductive microbiome. Obstet Med. 2019 Sep;12(3):107-115. doi: 10.1177/1753495X18775899. Epub 2018 May 17. — View Citation

Singh AS, Mulder C, Twisk JW, van Mechelen W, Chinapaw MJ. Tracking of childhood overweight into adulthood: a systematic review of the literature. Obes Rev. 2008 Sep;9(5):474-88. doi: 10.1111/j.1467-789X.2008.00475.x. Epub 2008 Mar 5. — View Citation

Tanvig M. Offspring body size and metabolic profile - effects of lifestyle intervention in obese pregnant women. Dan Med J. 2014 Jul;61(7):B4893. — View Citation

Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. A core gut microbiome in obese and lean twins. Nature. 2009 Jan 22;457(7228):480-4. doi: 10.1038/nature07540. Epub 2008 Nov 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Gut and vaginal microbiota Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16S ribosomal ribonucleic acid (16SrRNA) gene amplification sequencing (V6-V8). Sequences will be assigned to operational taxonomic units (OTUs). Preconceptional (up to 1 year before pregnancy)
Primary Gut and vaginal microbiota Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs. First trimester (between 7-12 weeks gestational age)
Primary Gut and vaginal microbiota Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs. Second trimester (between 22-25 weeks gestational age)
Primary Gut and vaginal microbiota Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs. Third trimester (between 30-32 weeks gestational age)
Primary Gut and vaginal microbiota Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs. Antepartum (during delivery)
Primary Gut and vaginal microbiota Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs. Postpartum (6-8 weeks post delivery)
Secondary Gut virome Composition of gut virome, obtained by a rectal swab Preconceptional (up to 1 year before pregnancy)
Secondary Gut virome Composition of gut virome, obtained by a rectal swab First trimester (between 7-12 weeks gestational age)
Secondary Gut virome Composition of gut virome, obtained by a rectal swab Second trimester (between 22-24 weeks gestational age)
Secondary Gut virome Composition of gut virome, obtained by a rectal swab Third trimester (between 30-32 weeks gestational age)
Secondary Gut virome Composition of gut virome, obtained by a rectal swab Antepartum (during delivery)
Secondary Gut virome Composition of gut virome, obtained by a rectal swab Postpartum (6-8 weeks post delivery)
Secondary Maternal immune response Responses of maternal immune system advanced oxidation protein products (AOPP)) measured in chloramine units per gram of protein (micromol/g) obtained by blood withdrawal and measured in the lab. Preconceptional (up to 1 year before pregnancy)
Secondary Maternal immune response Responses of maternal immune system advanced oxidation protein products (AOPP)) measured in chloramine units per gram of protein (micromol/g) obtained by blood withdrawal and measured in the lab. First trimester (between 7-12 weeks gestational age)
Secondary Maternal immune response Responses of maternal immune system advanced oxidation protein products (AOPP)) measured in chloramine units per gram of protein (micromol/g) obtained by blood withdrawal and measured in the lab. Second trimester (between 22-24 weeks gestational age)
Secondary Maternal immune response Responses of maternal immune system advanced oxidation protein products (AOPP)) measured in chloramine units per gram of protein (micromol/g) obtained by blood withdrawal and measured in the lab. Third trimester (between 30-32 weeks gestational age)
Secondary Maternal immune response Responses of maternal immune system advanced oxidation protein products (AOPP)) measured in chloramine units per gram of protein (micromol/g) obtained by blood withdrawal and measured in the lab. Antepartum (during delivery)
Secondary Maternal immune response Responses of maternal immune system advanced oxidation protein products (AOPP)) measured in chloramine units per gram of protein (micromol/g) obtained by blood withdrawal and measured in the lab. Postpartum (6-8 weeks post delivery)
Secondary Maternal immune response Tumor necrosis factor-alpha (TNF-alpha) measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Preconceptional (up to 1 year before pregnancy)
Secondary Maternal immune response Tumor necrosis factor-alpha (TNF-alpha) measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. First trimester (between 7-12 weeks gestational age)
Secondary Maternal immune response Tumor necrosis factor-alpha (TNF-alpha) measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Second trimester (between 22-24 weeks gestational age)
Secondary Maternal immune response Tumor necrosis factor-alpha (TNF-alpha) measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Third trimester (between 30-32 weeks gestational age)
Secondary Maternal immune response Tumor necrosis factor-alpha (TNF-alpha) measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Antepartum (during delivery)
Secondary Maternal immune response Tumor necrosis factor-alpha (TNF-alpha) measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Postpartum (6-8 weeks post delivery)
Secondary Maternal immune response Interleukin-6 (IL-6), measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Preconceptional (up to 1 year before pregnancy)
Secondary Maternal immune response Interleukin-6 (IL-6), measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. First trimester (between 7-12 weeks gestational age)
Secondary Maternal immune response Interleukin-6 (IL-6), measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Second trimester (between 22-24 weeks gestational age)
Secondary Maternal immune response Interleukin-6 (IL-6), measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Third trimester (between 30-32 weeks gestational age)
Secondary Maternal immune response Interleukin-6 (IL-6), measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Antepartum (during delivery)
Secondary Maternal immune response Interleukin-6 (IL-6), measured in picograms per milliliter, obtained by blood withdrawal and measured in the lab. Postpartum (6-8 weeks post delivery)
Secondary Maternal immune response high sensitive C-reactive protein(hsCRP), measured in mg/L, obtained by blood withdrawal and measured in the lab. Preconceptional (up to 1 year before pregnancy)
Secondary Maternal immune response high sensitive C-reactive protein(hsCRP), measured in mg/L, obtained by blood withdrawal and measured in the lab. First trimester (between 7-12 weeks gestational age)
Secondary Maternal immune response high sensitive C-reactive protein(hsCRP), measured in mg/L, obtained by blood withdrawal and measured in the lab. Second trimester (between 22-24 weeks gestational age)
Secondary Maternal immune response high sensitive C-reactive protein(hsCRP), measured in mg/L, obtained by blood withdrawal and measured in the lab. Third trimester (between 30-32 weeks gestational age)
Secondary Maternal immune response high sensitive C-reactive protein(hsCRP), measured in mg/L, obtained by blood withdrawal and measured in the lab. Antepartum (during delivery)
Secondary Maternal immune response high sensitive C-reactive protein(hsCRP), measured in mg/L, obtained by blood withdrawal and measured in the lab. Postpartum (6-8 weeks post delivery)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; folate, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Preconceptional (up to 1 year before pregnancy)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; folate, measured in micromol/l, obtained by blood withdrawal and measured in the lab. First trimester (between 7-12 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; folate, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Second trimester (between 22-24 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; folate, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Third trimester (between 30-32 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; folate, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Antepartum (during delivery)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; folate, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Postpartum (6-8 weeks post delivery)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; Homocysteine, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Preconceptional (up to 1 year before pregnancy)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; Homocysteine, measured in micromol/l, obtained by blood withdrawal and measured in the lab. First trimester (between 7-12 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; Homocysteine, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Second trimester (between 22-24 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; Homocysteine, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Third trimester (between 30-32 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; Homocysteine, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Antepartum (during delivery)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; Homocysteine, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Postpartum (6-8 weeks post delivery)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; B-vitamin 12, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Preconceptional (up to 1 year before pregnancy)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; B-vitamin 12, measured in micromol/l, obtained by blood withdrawal and measured in the lab. First trimester (between 7-12 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; B-vitamin 12, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Second trimester (between 22-24 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; B-vitamin 12, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Third trimester (between 30-32 weeks gestational age)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; B-vitamin 12, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Antepartum (during delivery)
Secondary Maternal metabolic response Markers of the one-carbon metabolism; B-vitamin 12, measured in micromol/l, obtained by blood withdrawal and measured in the lab. Postpartum (6-8 weeks post delivery)
Secondary Clinical maternal outcome: gestational age Gestational age (amenorrhea duration) at delivery. Durante partum
Secondary Clinical maternal outcome: pre-eclampsia Pre-eclampsia is defined as the combination of gestational hypertension (systolic blood pressure = 140 mmHg and/or diastolic blood pressure = 90 mmHg (Korotkoff V) occurring after 20 weeks of gestation gestational age, measured twice, in a woman who previously had normal blood pressure) with proteinuria (= 300 mg/24 hours). from 20 weeks of gestation to <8 weeks postpartum
Secondary Clinical maternal outcome: hypertension Hypertension is defined as a systolic blood pressure = 140 mmHg and/or diastolic blood pressure = 90 mmHg (Korotkoff V) occurring after 20 weeks of gestation gestational age, measured twice, in a woman who previously had normal blood pressure. from 20 weeks of gestation to <8 weeks postpartum
Secondary Clinical maternal outcome: gestational diabetes Gestational diabetes defined as any form of hyperglycaemia detected during pregnancy, regardless ofwhether this abnormality disappears after pregnancy. Diagnosed through a 75 gr Oral Glucose Tolerance Test (OGTT) with a fasting venous value > 7 mmol/l or above 7.8 mmol/l after 2 hours. From the first positive pregnancy test to delivery
Secondary Fetal growth Fetal growth trajectories, Crown-Rump-Length (CRL) obtained by using ultrasound imaging. First trimester (Between 7-7+6 days of gestational age)
Secondary Fetal growth Fetal growth trajectories, Crown-Rump-Length (CRL) obtained by using ultrasound imaging. First trimester (Between 9-9+6 days of gestational age)
Secondary Fetal growth Fetal growth trajectories, Crown-Rump-Length (CRL) obtained by using ultrasound imaging. First trimester (Between 11-11+6 days of gestational age)
Secondary Fetal growth Fetal growth trajectories defined as Estimated Fetal Weight (EFW) (in grams) based on the measurements (in mm) of the Head circumference (HC), Biparietal diameter (BPD), Abdominal circumference (AC) and Femur length (FL) to be obtained/measured during the ultrasound. Second trimester (Between AD 22-25 weeks of gestational age)
Secondary Fetal growth Fetal growth trajectories defined as Estimated Fetal Weight (EFW) (in grams) based on the measurements (in mm) of the Head circumference (HC), Biparietal diameter (BPD), Abdominal circumference (AC) and Femur length (FL) to be obtained/measured during the ultrasound. Third trimester (Between 30-33 weeks of gestational age)
Secondary Histological placental function Histology of placenta: biopsies are taken within 2 days after delivery, these are snapfrozen in -80 degrees Celsius and assessed according to protocol by pathologist Postpartum (<2 days postpartum)
Secondary Placental weight Placental weight measured (in grams), weighed on the scale. Postpartum (<2 days postpartum)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03249896 - Web/Smartphone-based Lifestyle Coaching Program in Pregnant Women With Gestational Diabetes N/A
Completed NCT06338254 - Efficacy of Percussion Massage Therapy Applied to the Lower Extremity on Pain, Edema in Pregnant Women N/A
Recruiting NCT04825093 - Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19 N/A
Completed NCT04739462 - SMS Maama Project COVID-19 N/A
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Recruiting NCT03313024 - Berlin-Brandenburg Pregnancy Cohort
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06357962 - Semi-permanent Acupuncture Effect on Cervical Ripening N/A
Not yet recruiting NCT06430853 - Psychobiological Interventions in Pregnancy N/A
Not yet recruiting NCT03661749 - Urinary Protein to Creatinine Ratio in Term Pregnant Women N/A
Completed NCT02970721 - Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
Completed NCT02191774 - Medical Abortion up to 10 Weeks Gestation at Home
Completed NCT01322529 - Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be N/A
Completed NCT00746551 - Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment Phase 4
Completed NCT00678080 - Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes N/A
Completed NCT00634530 - Impact of a Nutritional Intervention Program for Weight Control During Pregnancy N/A
Completed NCT00197561 - Partnership on Nutrition and HIV/AIDS Research in Tanzania: Exploratory Research Study on Selenium and HIV Infection Phase 3
Completed NCT05527327 - Pannus Retraction for Ultrasound Evaluation of the Obese Gravida: A Pilot Study N/A
Recruiting NCT05551078 - Thrombophilia Screening After Severe IUGR
Recruiting NCT03100084 - PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome